Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 39
- +7 vs. Q4 2023
- Portfolio value
- $1.50B
- +$351.0M (+30.7%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 4,360,000 | $196.3M | 13.1% | −387,373−8.2% | Reduced | History |
| VERAVera Therapeutics, Inc. | CL A | 3,165,000 | $136.5M | 9.1% | −2,285,000−41.9% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 1,487,756 | $111.7M | 7.5% | +156,719+11.8% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,167,793 | $93.3M | 6.2% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,884,084 | $71.5M | 4.8% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,973,245 | $69.9M | 4.7% | +1,071,429+36.9% | Added | History |
| PCVXVaxcyte, Inc. | COM | 860,000 | $58.7M | 3.9% | −240,000−21.8% | Reduced | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 5,833,333 | $54.8M | 3.7% | +5,833,333 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,375,000 | $54.5M | 3.6% | −235,000−14.6% | Reduced | History |
| ARVNArvinas, Inc. | COM | 1,275,000 | $52.6M | 3.5% | +275,000+27.5% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 1,050,000 | $45.5M | 3.0% | −500,000−32.3% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 6,425,000 | $43.2M | 2.9% | +858,974+15.4% | Added | History |
| PHVSPharvaris N.V. | COM | 1,725,000 | $39.9M | 2.7% | +925,000+115.6% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 866,468 | $36.4M | 2.4% | +164,501+23.4% | Added | History |
| NKTXNkarta, Inc. | COM | 3,165,000 | $34.2M | 2.3% | +435,000+15.9% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,934,653 | $33.9M | 2.3% | +10,579+0.5% | Added | History |
| CELCCelcuity Inc. | COM | 1,555,954 | $33.6M | 2.2% | −198,750−11.3% | Reduced | History |
| KURAKura Oncology, Inc. | COM | 1,525,000 | $32.5M | 2.2% | +276,938+22.2% | Added | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,410,384 | $27.9M | 1.9% | −389,616−10.3% | Reduced | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,000,000 | $27.5M | 1.8% | +2,000,000 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,895,003 | $27.1M | 1.8% | 00.0% | Unchanged | History |
| CATXPerspective Therapeutics, Inc. | COM | 21,052,631 | $25.1M | 1.7% | +21,052,631 | New | History |
| IMVTImmunovant, Inc. | COM | 750,990 | $24.3M | 1.6% | −249,010−24.9% | Reduced | History |
| KYTXKyverna Therapeutics, Inc. | COM | 912,189 | $22.7M | 1.5% | +912,189 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 1,250,000 | $21.2M | 1.4% | +1,250,000 | New | History |
| APGEApogee Therapeutics, Inc. | COM | 290,000 | $19.3M | 1.3% | +40,000+16.0% | Added | History |
| CABACabaletta Bio, Inc. | COM | 1,100,000 | $18.8M | 1.3% | −800,000−42.1% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 2,300,000 | $14.7M | 1.0% | +2,300,000 | New | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,250,000 | $11.8M | 0.8% | +543,294+76.9% | Added | History |
| NGNENeurogene Inc. | COM | 200,000 | $10.2M | 0.7% | +200,000 | New | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 657,333 | $9.29M | 0.6% | −342,667−34.3% | ReducedConverted for a 1-for-10 split | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $8.32M | 0.6% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 318,851 | $7.59M | 0.5% | +318,851 | New | History |
| SLNOSoleno Therapeutics Inc | COM | 169,533 | $7.26M | 0.5% | −530,467−75.8% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.20M | 0.3% | +500,000 | New | History |
| MGNXMacrogenics Inc | COM | 295,020 | $4.34M | 0.3% | +295,020 | New | History |
| ACETAdicet Bio, Inc. | COM | 1,374,320 | $3.23M | 0.2% | +1,374,320 | New | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 183,174 | $831.6K | 0.1% | 00.0% | UnchangedConverted for a 1-for-10 split | History |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $69.4K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2023 (4)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| RYZBRayzeBio, Inc. | COM | 383,638 | $23.9M | 2.1% | History |
| HARPHarpoon Therapeutics, Inc. | COM NEW | 1,500,000 | $17.1M | 1.5% | History |
| AKROAkero Therapeutics, Inc. | COM | 565,000 | $13.2M | 1.2% | History |
| DYNDyne Therapeutics, Inc. | COM | 900,000 | $12.0M | 1.0% | History |